Nasus Pharma Ltd (NSRX) stock

NSRXNYSEPharmaceutical PreparationsFiscal year ends December 31

Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Mar 25, 2026Score 6/30

$2.87+0.05 (+1.77%)

Close on Nov 13, 2026Market cap $25.87MP/E –Yield –

Nasus Pharma ebitda

EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.

Nasus Pharma has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.

Parsed from the XBRL in Nasus Pharma's annual and quarterly filings with the SEC
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is NSRX.

Operating margin-0.4% · median 10.2%

Net margin-0.5% · median 11.6%

Advertisement
300 × 250

See a number that looks wrong?